CNS Pharma receives Nasdaq minimum bid deficiency; ineligible for cure due to reverse splits

CNS Pharmaceuticals, Inc.

Nasdaq notified CNS Pharma on Sept 12, 2024 that common stock failed to maintain $1.00 minimum bid for 30 consecutive days.
Company ineligible for 180-day cure period because it effected reverse stock splits with cumulative ratio >=250 in prior two years.
Company intends to request a hearing before Nasdaq Panel; request will automatically stay any suspension/delisting pending hearing.
No assurance that Panel will grant an extension or that company will ultimately regain compliance with listing requirements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.